Northwest Biotherapeutics Secures $5.505 Million Loan

Northwest Biotherapeutics entered into a 22-month commercial loan agreement with Streeterville Capital, carrying 8% annual interest and a 10% original issue discount, to fund ongoing operations. No repayments are due for the first eight months.